CN108514109A - 麻醉术后专用型临床营养配方及其制备方法 - Google Patents
麻醉术后专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN108514109A CN108514109A CN201810445029.9A CN201810445029A CN108514109A CN 108514109 A CN108514109 A CN 108514109A CN 201810445029 A CN201810445029 A CN 201810445029A CN 108514109 A CN108514109 A CN 108514109A
- Authority
- CN
- China
- Prior art keywords
- parts
- postoperative
- powder
- anesthesia
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 64
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 48
- 230000035764 nutrition Effects 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000009472 formulation Methods 0.000 title description 9
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 89
- 230000037005 anaesthesia Effects 0.000 claims abstract description 89
- 229940088594 vitamin Drugs 0.000 claims abstract description 35
- 229930003231 vitamin Natural products 0.000 claims abstract description 35
- 235000013343 vitamin Nutrition 0.000 claims abstract description 35
- 239000011782 vitamin Substances 0.000 claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000035622 drinking Effects 0.000 claims abstract description 24
- 235000008216 herbs Nutrition 0.000 claims abstract description 23
- 230000010354 integration Effects 0.000 claims abstract description 23
- 239000004615 ingredient Substances 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 239000011573 trace mineral Substances 0.000 claims abstract description 16
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 16
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 14
- 235000005911 diet Nutrition 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 230000037213 diet Effects 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 91
- 235000013350 formula milk Nutrition 0.000 claims description 40
- 239000003921 oil Substances 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 36
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 34
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 32
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 28
- 235000015097 nutrients Nutrition 0.000 claims description 23
- 235000013399 edible fruits Nutrition 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 18
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 17
- 241000287828 Gallus gallus Species 0.000 claims description 17
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 17
- 244000131360 Morinda citrifolia Species 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 17
- 235000021342 arachidonic acid Nutrition 0.000 claims description 17
- 229940114079 arachidonic acid Drugs 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 17
- 235000017524 noni Nutrition 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 17
- 229910052725 zinc Inorganic materials 0.000 claims description 17
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 16
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 16
- 210000004317 gizzard Anatomy 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 15
- 241000218231 Moraceae Species 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 15
- 235000019197 fats Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 235000004347 Perilla Nutrition 0.000 claims description 8
- 244000124853 Perilla frutescens Species 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- -1 is uniformly mixed Substances 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- 241000206575 Chondrus crispus Species 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 102000040350 B family Human genes 0.000 claims description 5
- 108091072128 B family Proteins 0.000 claims description 5
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 5
- 240000001341 Reynoutria japonica Species 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 229920001503 Glucan Polymers 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 4
- 235000008599 Poria cocos Nutrition 0.000 claims description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 4
- 244000046146 Pueraria lobata Species 0.000 claims description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- 239000004519 grease Substances 0.000 claims description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 244000111489 Gardenia augusta Species 0.000 claims description 3
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims description 3
- 108010001441 Phosphopeptides Proteins 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000020243 first infant milk formula Nutrition 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 235000020429 malt syrup Nutrition 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 241000218645 Cedrus Species 0.000 claims 1
- 241000219780 Pueraria Species 0.000 claims 1
- 241000220324 Pyrus Species 0.000 claims 1
- 235000021017 pears Nutrition 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 22
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 20
- 238000002695 general anesthesia Methods 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 15
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- 229930003427 Vitamin E Natural products 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- 235000019165 vitamin E Nutrition 0.000 description 11
- 239000011709 vitamin E Substances 0.000 description 11
- 229940046009 vitamin E Drugs 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 208000018875 hypoxemia Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 7
- 102000015636 Oligopeptides Human genes 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 235000013734 beta-carotene Nutrition 0.000 description 7
- 239000011648 beta-carotene Substances 0.000 description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 7
- 229960002747 betacarotene Drugs 0.000 description 7
- 229960000304 folic acid Drugs 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- 229940055726 pantothenic acid Drugs 0.000 description 7
- 235000019161 pantothenic acid Nutrition 0.000 description 7
- 239000011713 pantothenic acid Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 239000011691 vitamin B1 Substances 0.000 description 7
- 239000011715 vitamin B12 Substances 0.000 description 7
- 239000011716 vitamin B2 Substances 0.000 description 7
- 239000011647 vitamin D3 Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- 102000010445 Lactoferrin Human genes 0.000 description 6
- 108010063045 Lactoferrin Proteins 0.000 description 6
- 206010061876 Obstruction Diseases 0.000 description 6
- 240000002924 Platycladus orientalis Species 0.000 description 6
- 208000004550 Postoperative Pain Diseases 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 6
- 229940078795 lactoferrin Drugs 0.000 description 6
- 235000021242 lactoferrin Nutrition 0.000 description 6
- 239000003589 local anesthetic agent Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- 208000009079 Bronchial Spasm Diseases 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101710089165 Protein white Proteins 0.000 description 5
- 208000010378 Pulmonary Embolism Diseases 0.000 description 5
- 206010038743 Restlessness Diseases 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010021133 Hypoventilation Diseases 0.000 description 4
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000003132 food thickener Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 235000015816 nutrient absorption Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003598 Atelectasis Diseases 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 2
- 244000061508 Eriobotrya japonica Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010059138 Glossoptosis Diseases 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020591 Hypercapnia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000009612 Laryngismus Diseases 0.000 description 2
- 206010023891 Laryngospasm Diseases 0.000 description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 description 2
- 240000000759 Lepidium meyenii Species 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000002547 Rosa roxburghii Species 0.000 description 2
- 235000000640 Rosa roxburghii Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 201000009807 aspiration pneumonia Diseases 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 235000012902 lepidium meyenii Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229940043200 pentothal Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000002694 regional anesthesia Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940125725 tranquilizer Drugs 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000019510 Mendelson syndrome Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028629 Myoglobinuria Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010071229 Procedural haemorrhage Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 201000009408 aspiration pneumonitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000007987 cellular zinc ion homeostasis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000014486 central sleep apnea syndrome Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001773 cervical plexus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 201000002972 idiopathic scoliosis Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BQMKAHQKDSZAIQ-UHFFFAOYSA-N tetrasodium;iron(3+);nitroxyl anion;pentacyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] BQMKAHQKDSZAIQ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种麻醉术后专用型临床营养配方,其特征在于,包括如下组分及其重量份数:40‑60份蛋白质、5‑15份脂肪、40‑50份碳水化合物、15‑25份膳食纤维、0.05‑1.2份常量元素、0.01‑0.05份微量元素、0.005‑0.03份脂溶性维生素、0.008‑0.2份水溶性维生素、0.1‑1份膳食精华、0.04‑0.8份药食同源成分、0.1‑3份天然植物化合物以及0.06‑1.32份新资源食品;本发明还提供上述临床营养配方的制备方法。本发明的临床营养配方能够根据麻醉术后患者的身体状况以及可能发生的各种并发症,提供均衡的营养物质,并能够减少麻醉术后患者的并发症、加快术后恢复。
Description
技术领域
本发明涉及营养配方领域,尤其涉及一种麻醉术后专用型临床营养配方及其制备方法。
背景技术
麻醉是施行手术时或进行诊断性检查操作为消除疼痛、保障病人安全、创造良好的手术条件而采取的各种方法,亦用于控制疼痛。进行手术或诊断性检查操作时,病人会感到疼痛,需要用麻醉药或其他方式使之暂时失去知觉。手术或检查操作还可引起精神紧张和反射性不良反应,如胃肠道手术可引起恶心、呕吐,长时间的不舒适的体位(如俯卧位),可增加病人的不适和痛苦。因此应使病人在舒适、安静的环境中,在对不良刺激无反应、暂时失去记忆的情况下接受手术,在这种情况下,麻醉成为了手术或检查操作时的重要选择。
麻醉主要包括全身麻醉、局部麻醉和复合麻醉,同时又根据麻醉药进入体的途径分为吸入麻醉、静脉麻醉(见全身麻醉)和基础麻醉。全身麻醉是将某些全身麻醉药(常用的有硫喷妥钠氯胺酮)肌肉注射,使病人进入睡眠状态,然后施行麻醉手术。局部麻醉为利用局部麻醉药如普鲁卡因、利多卡因等,使身体的某一部位暂时失去感觉,常用的方法包括椎管内麻醉(阻滞)、神经阻滞、区域阻滞、局部浸润麻醉和表面麻醉等;其中,椎管内麻醉(阻滞)是将局部麻醉药通过脊椎穿刺、注入到椎管内,其中注入蛛网膜下腔的称为蛛网膜下腔阻滞或腰麻,注入硬脊膜外腔的称为硬脊膜外腔阻滞;神经阻滞是将局部麻醉药注射到身体某神经干(丛)处,使其支配的区域产生痛觉传导阻滞,常用的神经阻滞有颈神经丛阻滞、臂神经丛阻滞;区域阻滞则是将局部麻醉药注射于手术部位的周围,使手术区域的神经末梢阻滞而达到麻醉的目的;局部浸润麻醉是直接将局部麻醉药注射至手术部位,并均匀地分布到整个手术区的各层组织内,以阻滞疼痛的传导,是临床小手术常用的麻醉方法;表面麻醉为将渗透性强的局部麻醉药如丁卡因等,喷雾或涂敷于粘膜、结膜等表面以产生麻醉作用。复合麻醉是麻醉中同时或先后应用两种或更多的麻醉药、辅助药(如镇痛药安定药等)或麻醉方法,使之相互配合截长补短,以增强麻醉效果,保障病人安全,以及满足某些手术的特殊要求;例如使用芬太尼,氟哌啶等施行神经安定镇痛麻醉;或者在全身麻醉下应用物理降温(全身冰水浴),从而降低全身代谢,增强组织对缺氧的耐受性的低温麻醉;或者使用降压药如硝普钠等,使动脉血压暂时下降到适当水平,以减少手术出血,便于手术操作的控制性低血压等;或者合并应用针刺或中草药和镇痛安定药的复合麻醉。医生应根据病情和手术需要、麻醉方法的适应症和禁忌症来选择麻醉方法。
但是,麻醉术后也会产生一些并发症,比如:
1.反流、误吸和吸入性肺炎
麻醉下发生呕吐或反流有可能招致严重的后果,胃内容物的误吸,以至造成急性呼吸道梗阻和肺部其他严重的并发症,是目前全麻患者死亡的重要原因之一。患者发生误吸导致急性肺损伤的程度,与误吸的胃内容物理化性质(如pH、含脂碎块及其大小)和容量,以及细菌的污染直接相关。
误吸的临床表现包括急性呼吸道梗阻、Mendelson综合征、吸入性肺不张、吸入性肺炎等。预防误吸主要是针对构成误吸和肺损害的原因采取措施:
(1)减少胃内容量和提高胃液pH;
(2)降低胃内压,使其低于食管下端括约肌阻力;
(3)保护气道,尤当气道保护性反射消失或减弱时,更具有重要意义。误吸的处理关键在于及时发现和采取有效的措施,以免发生气道梗阻窒息和减轻急性肺损伤。具体措施包括重建通气道、支气管冲洗、纠正低氧血症、激素、气管镜检查、抗生素及其他支持疗法。
为了减少反流和误吸的可能性,手术患者常需要术前禁食水,通常禁食6~8小时,禁饮4小时,小儿可以控制在2小时。
2.躁动
全麻恢复期,大多数患者呈嗜睡、安静或有轻度定向障碍和脑功能逐渐恢复趋于正常,但仍有部分患者出现较大的情感波动,表现为不能控制的哭泣和烦躁(躁动)不安。躁动的出现除了与术前、术中用药有关外,术后疼痛等可能是引起躁动的重要因素。
3.全麻后苏醒延迟
全身麻醉停止给药后,患者一般在60~90分钟当可获得清醒,对指令动作、定向能力和术前的记忆得以恢复。若超过此时限神志仍不十分清晰,可认为全麻后苏醒延迟。引起全麻后苏醒延迟的常见原因有药物作用时间的延长、高龄、患者全身代谢性疾病、中枢神经系统的损伤等。
4.术后恶心与呕吐
术后恶心与呕吐(PONV)是全麻后很常见的问题,其会造成患者的不适而影响患者休息,其发生率为20%~30%,既往有相关病史、女性和吸入麻醉相对发生率高。危险因素有:
(1)倾向性因素如早期妊娠、糖尿病和焦虑的患者;
(2)胃容量增加;
(3)麻醉用药与方法中,方法以全麻比区域性麻醉多见,用药以氧化亚氮、氯胺酮以及新斯的明为多见;
(4)手术部位与方式牵拉卵巢和宫颈扩张术,腹腔镜手术,斜视纠正术以及中耳的手术等为多见;
(5)手术后疼痛应用阿片类药、低血压和大量饮水等。胃肠减压导管刺激也常引起呕吐。对有明显发生PONV倾向的患者才考虑使用药物,一般不需预防性用药。主要药物有丁酰苯类、吩噻嗪类、胃动力性药、抗胆碱能药、抗组胺药、5-羟色胺拮抗剂等。
4.支气管痉挛
在麻醉过程和手术后均可发生急性支气管痉挛,表现为支气管平滑肌痉挛性收缩,气道变窄,气道阻力骤然增加,呼气性呼吸困难,引起严重缺氧和CO2蓄积。若不即时予以解除,患者因不能进行有效通气,不仅会导致发生血流动力学的变化,甚至还会导致发生心律失常和心跳骤停。
发生支气管痉挛的原因有气道高反应性、与麻醉手术有关的神经反射、气管插管等局部刺激、应用了具有兴奋性迷走神经、增加气道分泌物促使组胺释放的麻醉药、肌松药或其他药物等。其中,气管插管等局部刺激是麻醉诱导期间发生气道痉挛最常见的原因。既往有呼吸道慢性炎症、抽烟或支气管哮喘史的患者发生率较高,麻醉期间避免应用可诱发支气管痉挛的药物。选用局麻药进行完善的咽喉部和气管表面的麻醉,阻断气道的反射,可防止因刺激气道而诱发支气管痉挛。支气管痉挛的处理包括:明确诱因、消除刺激因素;如因麻醉过浅所致,则应加深麻醉;面罩吸氧,必要时施行辅助或控制呼吸;静脉输注皮质类固醇类药、氨茶碱等,两药同时应用可能收效更好。
5.低氧血症和通气不足
呼吸系统的并发症仍是全身麻醉后延缓术后康复、威胁患者生命安危的主要原因之一。全麻后气道阻塞最常见的原因,是因神志未完全恢复,舌后坠而发生咽部的阻塞;喉阻塞则可因喉痉挛或气道直接损伤所致。对舌后坠采用最有效的手法,是患者头后仰的同时,前提下颌骨,下门齿反咬于上门齿。据患者不同的体位进行适当的调整,以达到气道完全畅通。如果上述手法处理未能解除阻塞,则应置入鼻咽或口咽气道。但在置入口咽气道时,有可能诱发患者恶心、呕吐、甚至喉痉挛,故应需密切观察。极少数患者才需重行气管内插管。
1.低氧血症不仅是全身麻醉后常见的并发症,而且可导致严重的后果,甚至昏迷、死亡。易于引起麻醉后低氧血症的因素有:
(1)患者的年龄>65岁;
(2)体重超重的患者,如>100kg;
(3)施行全身麻醉的患者要比区域性麻醉更易于发生;
(4)麻醉时间>4小时;
(5)施行腹部手术者对呼吸的影响显著于胸部,以肢体手术的影响较为轻微;
(6)麻醉用药:如苯二氮卓类与阿片类药物并用,用硫喷妥钠诱导麻醉对呼吸的影响要显著于异丙酚。
2.通气不足系指因肺泡通气的降低引起PaCO2的增高。手术后通气不足的原因有:
(1)中枢性呼吸驱动的削弱;
(2)呼吸肌功能恢复的不足;
(3)体内产生CO2增多;
(4)由于呼吸系统急性或慢性疾病所影响。
6.急性肺不张
急性肺不张是指患者骤然出现肺段、肺叶或一侧肺的萎陷,从而丧失通气的功能。急性肺不张是手术后严重的并发症之一,尤其多见于全身麻醉之后。大面积急性肺不张,可因呼吸功能代偿不足,使患者因严重缺氧而致死。
发生急性肺不张的危险因素为:围手术期患者存在有急性呼吸道感染,呼吸道急性或慢性梗阻;术后最常见的原因是气道被黏稠的分泌物所堵塞、慢性气管炎、吸烟、肥胖、老年患者肺容量小,如非阻塞性肺病,胸廓畸形,或因肌肉、神经肌肉和神经疾病所致的呼吸肌障碍或受限。
7.通气不足综合征
中枢性或梗阻性睡眠-呼吸暂停综合征患者。
手术后发生肺不张的危险因素包括:
(1)呼吸道分泌物多,且引流或排出不畅;
(2)胸部或上腹部大手术患者;
(3)外科手术切口疼痛;
(4)镇痛药应用不当;
(5)应用具抑制中枢神经系统的药物。
8.高血压
全身麻醉恢复期,随着麻醉药作用的消退、疼痛不适,以及吸痰、拔除气管内导管的刺激等原因极易引起高血压的发生。尤其先前有高血压病史者,且多始于手术结束后30分钟内。如果在术前突然停用抗高血压药物,则发生高血压情况更呈严重。发生高血压的原因包括:疼痛、低氧血症与高碳酸血症、术中补充液体超荷(volumeoverload)和升压药应用不当、吸痰的刺激、和其他如术后寒战,尿潴留膀胱高度膨胀等。
9.脑血管意外
患者先前多存在有脑血管病,而在麻醉手术过程(围手术期)中,意外地发生了脑卒中,其中约有80%是因脑血管供血不足(或血流太少),称为缺血性卒中,另外20%则属于出血性卒中(如脑实质性出血和蛛网膜下腔出血)。卒中所涉及的范围,可以是局灶性、多灶性,也可以是弥散性,反映出因单一或多个血管的病理改变而引起脑功能急速的障碍。高龄(超过65岁)、高血压、糖尿病、外展血管病变、心脏疾病(冠心病和房颤等)等都是围术期发生脑血管意外的高危因素。
全身麻醉期间因为患者处于睡眠状态,对患者意识和肌力的监测受到影响,可能不能及时发现脑卒中的发生。
10.恶性高热
恶性高热(MH)是由吸入强效的挥发性麻醉药和琥珀胆碱诱发的骨骼肌异常高代谢状态,呼出CO2和体温骤然增高、心动过速,并出现肌红蛋白尿等。MH以白种人多发,但在不同种族中均有报道,说明MH并非种族特异性。儿童MH发病率(1/15000)明显高于成人(1/50000)。儿童好发年龄多在10岁以下,男性多于女性。MH以先天性疾病如特发性脊柱侧弯、斜视、上睑下垂、脐疝、腹股沟疝等多见,在其他外科疾病中也有散在报道。目前认为MH是一种具有家族遗传性的亚临床肌肉病。MH的临床表现可分为爆发型(22%)、咬肌痉挛型(22%)和流产型(57%)。爆发型最严重,表现为突然发生的高碳酸血症和高钾血症、快速心律失常、严重缺氧和酸中毒、体温急剧升高,可达45℃~46℃。多数患者在数小时内死于顽固性心律失常和循环衰竭。
麻醉手术后患者大都只注重高蛋白的补充,忽视了各种特殊营养的补充。因而,针对这种情况,研制一种在补充基本营养和高蛋白的同时,能够根据麻醉术后患者的各种可能发生的并发症,补充相应的特殊营养以减少麻醉术后患者的并发症,加快患者术后恢复的营养产品,具有重要价值和广阔的市场。
发明内容
本发明的目的在于克服现有技术中的缺陷,提供一种麻醉术后专用型临床营养配方及其制备方法,能够根据麻醉术后患者的身体状况以及可能发生的各种并发症,提供均衡的营养物质,并能够减少麻醉术后患者的并发症、提高患者机体免疫能力、加快患者术后恢复。
为实现上述目的,本发明采用如下技术方案:
本发明的第一个目的是提供一种麻醉术后专用型临床营养配方,包括如下组分及其重量份数:40-60份蛋白质、5-15份脂肪、40-50份碳水化合物、15-25份膳食纤维、0.05-1.2份常量元素、0.01-0.05份微量元素、0.005-0.03份脂溶性维生素、0.008-0.2份水溶性维生素、0.1-1份膳食精华、0.04-0.8份药食同源成分、0.1-3份天然植物化合物以及0.06-1.32份新资源食品;
其中,所述药食同源成分包括茯苓、栀子、金银花、葛根、沙棘、鸡内金、橘皮、桑葚中的至少一种;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
为了进一步优化上述技术方案,本发明所采取的技术措施还包括:
进一步地,所述蛋白质包括乳清蛋白粉、大豆分离蛋白、水解鱼胶原蛋白、全脂奶粉、脱脂奶粉、全蛋粉、乳铁蛋白、牛初乳、氨基酸和蛋白肽中的至少一种;其中,所述氨基酸包括L-赖氨酸-L-谷氨酸、L-谷氨酸、L-精氨酸、L-色氨酸、L-谷氨酰胺、牛磺酸、L-缬氨酸、L-异亮氨酸、L-亮氨酸中的至少一种;所述蛋白肽包括大豆低聚肽、小麦蛋白肽、蚕蛹蛋白肽、海洋鱼低聚肽粉、可乐肽、氨基肽、卵白蛋白肽中的至少一种。
进一步地,所述脂肪包括饱和脂肪酸、多不饱和脂肪酸、单不饱和脂肪酸、OPO结构脂、DHA、EPA、ARA、磷脂中的至少一种。
进一步地,所述碳水化合物包括果糖、冰糖、乳糖、麦芽糊精、木薯淀粉、抗性淀粉中的至少一种。
进一步地,所述膳食纤维包括菊粉、魔芋粉、低聚半乳糖、低聚果糖、低聚异麦芽糖、大豆多糖、环糊精、抗性糊精、大豆纤维中的至少一种。
进一步地,所述常量元素包括檬酸钙、L-乳酸钙、磷酸氢钙、葡萄糖酸钙、柠檬酸钾、氯化钾、葡萄糖酸钾、氯化钠、柠檬酸钠和葡萄糖酸镁、碳酸镁、硫酸镁中的至少一种。
进一步地,所述微量元素包括葡萄糖酸亚铁、硫酸亚铁、碘化钾、柠檬酸锌、葡萄糖酸锌、亚硒酸钠、硫酸铜、葡萄糖酸铜、硫酸铬、氯化铬、葡萄糖酸锰、硫酸锰、和钼酸钠中的至少一种。
进一步地,所述微量元素包括0.02-0.1份锌;更进一步地,所述微量元素包括0.02-0.04份锌。
进一步地,所述脂溶性维生素包括维生素A、β-胡萝卜素、维生素D3、维生素E、维生素K1中的至少一种;更进一步地,所述脂溶性维生素包括维生素A、β-胡萝卜素、维生素D3、维生素E。
进一步地,所述水溶性维生素包括维生素B1、维生素B2、维生素B6、维生素B12、维生素C、泛酸、叶酸、烟酸、胆碱、肌醇、生物素中的至少一种;更进一步地,所述水溶性维生素包括维生素B1、维生素B2、维生素B6、维生素B12、维生素C、泛酸、叶酸、烟酸。
进一步地,所述维生素E和所述维生素C的总的重量份数为0.15-0.25份;更进一步地,所述维生素E和所述维生素C的总的重量份数为0.18-0.2份。
进一步地,所述水溶性维生素包括0.003-0.01份的B族维生素。
进一步地,所述膳食精华包括谷类、豆类、薯类、蔬菜类、菌藻类、坚果种子类、鱼虾类、禽畜肉类、水果类中的至少一种;其中,所述谷类包括大米粉、小米粉、黑米粉、薏米粉、玉米粉、小麦胚芽粉、燕麦粉、荞麦粉中的至少一种;所述豆类包括豌豆粉、绿豆粉、黑豆粉、红豆粉、大豆粉中的至少一种;所述薯类主要由淮山粉组成;所述蔬菜类包括胡萝卜粉、白萝卜粉、南瓜粉、菠菜粉、番茄粉、西兰花粉、苦瓜粉中的至少一种;所述菌藻类包括香菇粉、海带粉、银耳粉中的至少一种;所述坚果种子类主要由南瓜子粉和莲子粉组成;所述鱼虾类包括三文鱼粉和鳕鱼粉中的至少一种;所述禽畜肉类包括鸡肉粉、牛肉粉、猪肾粉中的至少一种;所述水果类包括红枣粉、奇异果粉、桂圆粉、苹果粉、樱桃粉、柑橘粉、雪梨粉中的至少一种。
进一步地,所述药食同源成分包括鸡内金、沙棘、橘皮、桑葚;更进一步地,所述药食同源成分中各组分的重量份数为:鸡内金0.01-0.2份、沙棘0.01-0.2份、橘皮0.01-0.2份、桑葚0.01-0.2份。
进一步地,所述天然植物化合物的重量份数为0.1-1.5份。
进一步地,所述天然植物化合物包括左旋肉碱、氨基葡萄糖、低聚果糖、叶黄素、植物甾醇、番茄红素、白藜芦醇、大蒜素中的至少一种;更进一步地,所述天然植物化合物为左旋肉碱。
进一步地,所述新资源食品包括γ-氨基丁酸、DHA藻油、花生四烯酸油脂、诺丽果浆粉、磷脂酰丝氨酸、枇杷叶粉;更进一步地,所述新资源食品中各组分的重量份数为:γ-氨基丁酸0.01-0.15份、DHA藻油0.01-0.4份、花生四烯酸油脂0.01-0.15份、诺丽果浆粉0.01-0.4份、磷脂酰丝氨酸0.01-0.07份、枇杷叶粉0.01-0.15份。
进一步地,所述麻醉术后专用型临床营养配方还包括如下组分和重量份数的中药成分:何首乌0.05-0.1份、胡桃肉0.05-0.1份、酸枣仁0.05-0.1份、柏子仁0.05-0.1份。
本发明的第二个目的是提供一种上述麻醉术后专用型临床营养配方的制备方法,包括如下步骤:
步骤1,制备脂肪粉末;
步骤2,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤3,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤4,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳食精华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤5,将步骤1~4所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤6,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~4的顺序可相互更换。
进一步地,所述步骤1中制备脂肪粉末具体包括如下步骤:
1)制备壁材水溶液:取麦芽糊精36g、麦芽糖浆9g、酪蛋白酸钠3g、水50mL搅拌均匀;
2)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于6.1mL紫苏油中;
3)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于所述壁材水溶液中;
4)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合,得到混合溶液;
5)添加稳定剂琼脂0.1g(总固形物浓度为0.2%)于所述混合溶液后,用水定容至200mL(总固形物浓度为25%),20000r/min下高速分散2分钟,得到乳状液;
6)将所述乳状液在均质压力25MPa下,均质3次,每次5分钟,得到均质乳状液;
7)将所述均质乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃,收集得到脂肪粉末。
进一步地,所述步骤6中可选择性地增加适量的食品增稠剂和食品添加剂。所述食品增稠剂选自瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、阿拉伯胶中的至少一种;所述食品添加剂选自阿斯巴甜、食用香精香料、红糖中的至少一种;更优选为卡拉胶、阿拉伯胶、瓜尔胶、阿斯巴甜、食用香精香料。
进一步地,上述麻醉术后专用型临床营养配方的干法工艺的制备方法的操作步骤均需在惰性气体的保护下进行,所使用的惰性气体为氮气、氩气、氦气等。在惰性气体的保护下进行上述操作步骤可以防止产生粉末爆炸的危险。
本发明中采用包括鸡内金、沙棘、橘皮、桑葚的药食同源成分,上述成分配伍增效后具有理气调中、促进营养吸收、降低心脏负荷、促进血液循环、提高机体抗氧化能力,增强机体免疫能力、保护神经元细胞的功效。
鸡内金能够增强胃功能促进消化,并且通过鸡内金不同炮制品对小鼠肠胃推进功能的影响的试验中发现,鸡内金的消食作用并不是药物在胃内的局部作用或直接刺激肠胃运动引起的,可能是药物消化后进入血液刺激胃腺分泌增加而起到间接助消化作用;因此,添加鸡内金于本发明的临床营养配方中,既能够促进患者对其他营养组分的吸收,又不会对肠胃造成刺激,适合于麻醉术后患者食用;
沙棘营养丰富,含多种维生素、脂肪酸、微量元素、亚油素、沙棘黄酮、超氧化物等活性物质和人体所需的各种氨基酸;有研究表明,沙棘提取物对麻醉开胸犬具有降低总外周阻力和冠脉阻力的作用,降低总外周阻力和冠脉阻力可降低心脏的前后负荷,减轻射血阻力;沙棘提取物可明显增加心输出量、心肌血量、心脏指数和心搏指数;
橘皮具有理气调中,燥湿化痰功效,可用于治疗脾胃气滞,脘腹胀满,呕吐,或湿浊中阻所致胸闷、纳呆、便溏;
桑葚具有可用于疗例如滋补、止痛、失眠、耳鸣、头晕、背痛和便秘等,桑葚主要组分为花青素、酚酸和黄酮类等,其分离的单一组分和它的提取物具有降低血糖、MAO(单胺氧化酶)抑制活性、抗氧化效果和神经元细胞保护效果。
本发明中采用包括γ-氨基丁酸、DHA藻油、花生四烯酸油脂、诺丽果浆粉、磷脂酰丝氨酸、枇杷叶粉的新资源食品,上述成分配伍增效后具有能够防止麻醉术后对神经系统的损伤、减轻麻醉后对学习和记忆能力的损伤、促进神经内分泌活动、调节脑和神经的生理功能、增强免疫功能、增强术后患者的抗菌和抗病毒的能力、缓解术后疼痛、促进术后恢复、增加脑部供血、预防大脑受损的功效。
γ-氨基丁酸(GABA)在神经系统的发育过程中具有营养作用,是一种神经营养因子;在神经系统发育的早期,GABA可作为一种化学信号,影响神经元的运动,刺激神经元的迁移;GABA对一些细胞器尤其是对涉及合成与转运整合膜蛋白的细胞器影响较大,故GABA可促进整合膜蛋白的合成,包括GABA受体以及一些神经相关蛋白及酶的合成;GABA对一些神经相关蛋白及酶的表达也具有一定的调节作用,因此,γ-氨基丁酸能够防止麻醉术后对神经系统的损伤;
DHA藻油所含有的二十二碳六烯酸(docosahexaenoic acid,DHA)是n-3系列多不饱和脂肪酸、突触膜磷脂和视网膜感光细胞处富集存在;临床研究表明新生儿配方补充单独的DHA或者与ARA一起补充会提高其认知能为;动物研究显示,缺乏DHA会导致在认知活动和行为测试中的表现较差,而补充DHA可导致学习和记忆相关的机能恢复;在神经退行性疾病的动物模型中的研究表明,补充DHA可通过抑制氧化应激反应和炎症,诱导细胞存活的基因产生有利的影响;因此,DHA能够减轻麻醉后导致的学习和记忆能力的损伤;
花生四烯酸油脂具有广泛为重要的生理作用,特别是在降血脂、抑制血小板聚集、抗炎、抗癌和抗脂质氧化、促进脑组织发展等方面,具有独特的生物活性;花生四烯酸代谢途径中的环氧化酶异构酶,及下游的前列腺素合成酶和相应受体,都参与了炎症的发生及抗氧化过程,并发挥着重要的作用;花生四烯酸能够促进神经内分泌活动,并因此而调节脑和神经的生理功能,因此通过营养制剂补充花生四烯酸能够矫正因紧张脑力活动、精神压力造成的代谢和内分泌异常;
诺丽果中所含的7—羟—6—甲香豆素(scopoletin),可以使心血管快速松弛,达到降低血压的功效,同时其中所含的镁,可以调节心律,减低心绞痛,缓和肌肉痉挛;诺丽果中所含的维生素C和矿物质锌、硫、锗、硒、锰等均可以抵抗自由基,增强免疫功能,增强术后患者的抗菌和抗病毒的能力,避免术后感染;同时诺丽可以减缓气管和支气管分泌过多的粘液,对慢性支气管和肺气肿有很大的助益。诺丽果中的桑色素酊和檄树苷能预防细菌和病毒感染,强化呼吸系统;同时诺丽果中含有多种止痛成份,不但止痛性强,而且效果温和不会产生依赖性,有利于减轻患者的术后疼痛,避免患者发生躁动,有利于患者的术后恢复;
磷脂酰丝氨酸是脑部神经的主要成分之一,可营养和活化脑中各种酶的活性,能延缓神经递质的减少进程,有助于修复、更新大脑受损细胞和清除有害物质;磷脂酰丝氨酸和DHA可以相互促进吸收,对神经2A细胞起到保护作用,丰富的磷脂酰丝氨酸可以增加细胞膜的流动性,促进智力的发育;研究表明,磷脂酰丝氨酸之所以能够增强人的智力,主要原因在于它能够迅速穿过血脑屏障,进入大脑,在脑部起到舒缓大脑毛细血管平滑肌细胞,增加脑部供血的作用,并且磷脂酰丝氨酸对麻醉术后患者的大脑损伤也有一定的保护作用;
枇杷叶粉性苦,微寒。归肺、胃经,可用于清肺止咳,降逆止呕肺,可治疗热咳嗽.气逆喘息,胃热呕逆,烦热口渴。
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:
1)添加B族维生素0.003-0.01份,有研究显示,B族维生素能够改善麻醉术后患者认知功能障碍,添加上述重量份数的B族维生素于本发明的临床营养配方中,能够防止因麻醉手术导致的患者脑功能障碍。
2)添加锌0.02-0.1份,研究证实异氟醚麻醉具有潜在的(AD)神经毒性作用,长时间或重复暴露异氟醚能够促进AD神经病理进程和加剧AD病情的进展;锌是重要的生命元素,是维持大脑正常功能所必需的微量元素,与学习记忆等脑功能密切相关;最近研究证实Zn2+在神经变性疾病AD的发病机制中起着重要作用,Zn2+是AD病变时淀粉样斑块和淀粉样脑血管病的重要组成部分,Zn2+能够使神经细胞内tau高度磷酸化;在小鼠模型和AD病人的研究发现,AD时存在Zn2+稳态的失衡;研究表明锌稳态失衡(缺锌)能够加重AD模型小鼠神经病理进程和认知功能障碍,增加APP转基因小鼠中淀粉样蛋白斑块的容积,引起神经元严重损害,导致包括AD等在内多种神经变性疾病的发生;添加上述重量份数的微量元素锌于本发明的临床营养配方中,能够防止因麻醉手术导致的患者神经变性疾病的发生。
3)添加维生素E、维生素C共0.15-0.25份,研究显示,维生素C、维生素E能保护细胞在手术中免受脂质过氧化反应,维生素C、维生素E在术中对细胞的保护作用系通过抗氧化作用而实现的;脂质过氧化会导致新陈代谢失常和免疫功能降低,添加上述重量份数的维生素E和维生素C于本发明的临床营养配方中,能够改善麻醉术后患者的机体新陈代谢,提高机体免疫能力,进而提高身体质量,加快身体恢复。
4)添加包括何首乌、胡桃肉、酸枣仁、柏子仁的中药成分;何首乌内的卵磷脂是构成脑细胞的重要原料,能够提高脑细胞的活性化程度,同时卵磷脂还能调节胆固醇在人体内的含量、有效降低胆固醇、高血脂及冠心病的发病率;胡桃肉含、矿物质、蛋白质、卵磷脂和、维生素AD、E等,具有很好的营养脑细胞功能;酸枣仁具有提高机体抗氧化能力,增强机体免疫能力的功效,《酸枣仁对D-半乳糖致衰老模型小鼠大脑皮层抗氧化作用影响的实验研究》中发现,D-半乳糖会导致小鼠基体抗氧化能力下降,脂质过氧化程度增强,NO含量及MAO-B活性升高,而酸枣仁可通过显著小鼠抗氧化酶活性,提高机体抗氧化能力,降低小鼠的脂质过氧化水平和NO含量、MAO-B活性;柏子仁具有养心安神之效,近代药理证实,柏子仁确有镇静、催眠作用,亦有试验表明用柏子仁煎剂给大白鼠口服或腹腔注射,无论白天或黑夜,均表现出良好的镇静及嗜眠效应;上述中药成分配伍增效后具有营养大脑、改善脑功能、提高机体抗氧化能力、增强机体免疫能力、镇静之效,添加于本发明的临床营养配方中,有助于防止因麻醉手术导致的患者脑功能障碍,促进麻醉术后患者提高身体质量,避免术后躁动,加快身体恢复。
本发明通过选用合理配比的基础营养素,采用低脂肪比例,同时添加具有防止麻醉术后患者脑功能障碍、保护患者神经元细胞、促进营养吸收、增强免疫功能、增强术后患者的抗菌和抗病毒的能力、缓解术后疼痛、促进术后恢复的膳食纤维、膳食精华、天然植物化合物、药食同源成分、新资源食品等特殊营养物质,并调整其配比与基础营养素进行配伍增效,使的本发明的麻醉术后专用型临床营养配方能够更好地被麻醉术后患者吸收,从而充分发挥各组分的功效,减少麻醉术后患者的并发症,加快患者术后恢复。
具体实施方式
本发明提供了一种麻醉术后专用型临床营养配方,包括如下组分及其重量份数:40-60份蛋白质、5-15份脂肪、40-50份碳水化合物、15-25份膳食纤维、0.05-1.2份常量元素、0.01-0.05份微量元素、0.005-0.03份脂溶性维生素、0.008-0.2份水溶性维生素、0.1-1份膳食精华、0.04-0.8份药食同源成分、0.1-3份天然植物化合物以及0.06-1.32份新资源食品;其中,所述药食同源成分包括茯苓、栀子、金银花、葛根、沙棘、鸡内金、橘皮、桑葚中的至少一种;其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
下面通过具体实施例对本发明进行详细和具体的介绍,以使更好的理解本发明,但是下述实施例并不限制本发明范围。
实施例1
本发明所述的麻醉术后专用型临床营养配方包括乳清蛋白粉22.3g、大豆分离蛋白3.7g、脱脂奶粉29.8g、乳铁蛋白0.4g、海洋鱼低聚肽0.15g、牛磺酸0.45g;紫苏油5.5g;麦芽糊精40.47g;膳食纤维15g;钙0.15g;铁0.03g、锌0.02g;维生素A 0.0014g、β-胡萝卜素0.017g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.003g、维生素B2 0.003g、维生素B6 0.003g、维生素B12 0.000005g、维生素C 0.163g、泛酸0.003g、叶酸0.00013g、烟酸0.0124g;奇异果粉0.75g;鸡内金0.15g、沙棘0.15g、橘皮0.15g、桑葚0.15g;γ-氨基丁酸0.15g、DHA藻油0.4g、花生四烯酸油脂0.15g、诺丽果浆粉0.4g、磷脂酰丝氨酸0.07g、枇杷叶粉0.15g;左旋肉碱1.5g。
实施例2
本发明所述的麻醉术后专用型临床营养配方包括乳清蛋白粉22.3g、大豆分离蛋白3.7g、脱脂奶粉29.8g、乳铁蛋白0.4g、海洋鱼低聚肽0.15g、牛磺酸0.45g;紫苏油5.5g;麦芽糊精40.47g;膳食纤维15g;钙0.15g;铁0.03g、锌0.02g;维生素A 0.0014g、β-胡萝卜素0.017g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.003g、维生素B2 0.003g、维生素B6 0.003g、维生素B12 0.000005g、维生素C 0.163g、泛酸0.003g、叶酸0.00013g、烟酸0.0124g;奇异果粉0.75g;茯苓0.15g、沙棘0.15g、葛根0.15g、桑葚0.15g;燕麦β-葡聚糖0.15g、低聚木糖0.4g、花生四烯酸油脂0.15g、诺丽果浆粉0.4g、磷脂酰丝氨酸0.07g、枇杷叶粉0.15g;左旋肉碱1.5g。
实施例3
本发明所述的麻醉术后专用型临床营养配方包括乳清蛋白粉22.3g、大豆分离蛋白3.7g、脱脂奶粉29.8g、乳铁蛋白0.4g、海洋鱼低聚肽0.15g、牛磺酸0.45g;紫苏油5.5g;麦芽糊精40.47g;膳食纤维15g;钙0.15g;铁0.03g、锌0.02g;维生素A 0.0014g、β-胡萝卜素0.017g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.003g、维生素B2 0.003g、维生素B6 0.003g、维生素B12 0.000005g、维生素C 0.163g、泛酸0.003g、叶酸0.00013g、烟酸0.0124g;奇异果粉0.75g;鸡内金0.15g、沙棘0.15g、橘皮0.15g、桑葚0.15g;γ-氨基丁酸0.15g、DHA藻油0.4g、花生四烯酸油脂0.15g、诺丽果浆粉0.4g、磷脂酰丝氨酸0.07g、枇杷叶粉0.15g;左旋肉碱1.5g;何首乌0.05g、胡桃肉0.05g、酸枣仁0.05g、柏子仁0.05g。
实施例4
本发明所述的麻醉术后专用型临床营养配方包括乳清蛋白粉22.3g、大豆分离蛋白3.7g、脱脂奶粉29.8g、乳铁蛋白0.4g、海洋鱼低聚肽0.15g、牛磺酸0.45g;紫苏油5.5g;麦芽糊精40.47g;膳食纤维15g;钙0.15g;铁0.03g、锌0.02g;维生素A 0.0014g、β-胡萝卜素0.017g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.003g、维生素B2 0.003g、维生素B6 0.003g、维生素B12 0.000005g、维生素C 0.163g、泛酸0.003g、叶酸0.00013g、烟酸0.0124g;奇异果粉0.75g;鸡内金0.01g、沙棘0.01g、橘皮0.01g、桑葚0.01g;γ-氨基丁酸0.15g、DHA藻油0.4g、花生四烯酸油脂0.15g、诺丽果浆粉0.4g、磷脂酰丝氨酸0.07g、枇杷叶粉0.15g;左旋肉碱1.5g。
实施例5
本发明所述的麻醉术后专用型临床营养配方包括乳清蛋白粉22.3g、大豆分离蛋白3.7g、脱脂奶粉29.8g、乳铁蛋白0.4g、海洋鱼低聚肽0.15g、牛磺酸0.45g;紫苏油5.5g;麦芽糊精40.47g、;膳食纤维15g;钙0.15g;铁0.03g、锌0.02g;维生素A 0.0014g、β-胡萝卜素0.017g、维生素D3 0.000001g、维生素E 0.009g;维生素B1 0.003g、维生素B2 0.003g、维生素B6 0.003g、维生素B12 0.000005g、维生素C 0.163g、泛酸0.003g、叶酸0.00013g、烟酸0.0124g;奇异果粉0.75g;鸡内金0.15g、沙棘0.15g、橘皮0.15g、桑葚0.15g;γ-氨基丁酸0.01g、DHA藻油0.01g、花生四烯酸油脂0.01g、诺丽果浆粉0.01g、磷脂酰丝氨酸0.01g、枇杷叶粉0.01g;左旋肉碱1.5g。
实施例6
一种如实施例1~实施例5所述的麻醉术后专用型临床营养配方的制备方法如下:
1)制备粉末油脂(粉末脂肪):
a)制备壁材水溶液:取麦芽糊精36g、麦芽糖浆9g、酪蛋白酸钠3g、水50毫升搅拌均匀(有条件边加热边搅拌至60℃,保持30分钟后冷却至室温)。
b)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于6.1mL紫苏油中。
c)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于壁材水溶液中。
d)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合。
e)添加稳定剂琼脂取0.1g(总固形物浓度为0.2%)进混合溶液后,用水定容至200mL(总固形物浓度为25%),20000r/min下高速分散2分钟。
f)均质压力为25MPa,均质3次(每次5分钟),制得均质乳状液。
g)将制得的乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃。收集粉末油脂(粉末脂肪)。
2)制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
3)制备维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
4)将预定重量的蛋白质和氨基酸、核苷酸、碳水化合物、膳食纤维、常量元素、微量元素、膳食精华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
5)将步骤1)~步骤4)所制得的粉末依次加入锥形混合机或其他形式的混合机混合均匀制得配方混合物,经过杀菌处理后,备用;
6)根据常规技术手段将步骤5)中的配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种。
在步骤6)中,可选择性地增加适量的食品增稠剂和食品添加剂。所述食品增稠剂为瓜尔胶、黄原胶、槐豆胶、魔芋胶、果胶、卡拉胶、琼脂、明胶、阿拉伯胶中的至少一种,所述食品添加剂为阿斯巴甜、食用香精香料、红糖中的至少一种;更优选卡拉胶、阿拉伯胶、瓜尔胶、阿斯巴甜、食用香精香料。
上述操作步骤均需在惰性气体的保护下进行,比如氮气、氩气、氦气等,以防止产生粉末爆炸的危险。
按照所述配方可制备成粉状、颗粒状、胶囊状、片剂状、饮料等类别。
实施例7
本实施例为验证实施例。
本验证实施例验证本发明所述的麻醉术后专用型临床营养配方对麻醉术患者的影响。本实施例采用实施例1、2和3的配方制备的营养粉以及下述对比例:
对照组:采用常规营养粉;
实验组1:采用实施例1的营养配方制备的营养粉;
实验组2:采用实施例2的营养配方制备的营养粉;
实验组3:采用实施例3的营养配方制备的营养粉;
实验组4:采用实施例1的营养配方中删除药食同源成分的营养粉;
实验组5:采用实施例1的营养配方中删除新资源食品制备的营养粉;
实验组6:采用实施例1的营养配方中删除微量元素锌制备的营养粉;
以上每组选用自愿服用相应营养粉的麻醉术患者20名,均为全身麻醉患者;在维持正常输液和其他常规治疗期间给予上述营养粉食用;早中晚3次,冲服,2d后进行实验结果统计,
统计指标为:
一、气道通畅程度(0-气道不通畅,即患者不能自行保持气道通畅;或1-气道通畅,即患者能够自行保持气道通畅);
二、意识恢复程度(0-意思恢复不良,即患者的OAA/S评分≤3份;或1-意识恢复良好,即患者的OAA/S评分>3份);
三、疼痛程度(0-疼痛,即患者的Likert计分>3分;或1-不疼痛,即患者的Likert计分≤3分);
四、低氧程度(0-低氧,即患者吸空气条件下SpO2低于术前;或1-不低氧,即患者吸空气条件下SpO2不低于术前)
实验结果如表1:
表1 本发明所述的麻醉术后专用型临床营养配方对麻醉术患者恢复的治疗效果(n(%))
从上表可知,本发明所述的麻醉术后专用型临床营养配方可以明显改善麻醉术的患者的身体恢复状况。未添加本发明的药食同源成分、新资源食品或微量元素锌的临床营养配方其效果高于采用常规营养粉的对照组,但略低于添加了本发明的药食同源成分、新资源食品和微量元素锌的临床营养配方的实验组。说明药食同源成分、新资源食品或微量元素锌等组分对于改善麻醉术后症状效果的实现是必不可少的,其与本发明其他组分相辅相成,充分发挥各自的功效,才能取得优异的效果。
由上述实施例可知,本发明所述的麻醉术后专用型临床营养配方能够根据麻醉术后患者的身体状况以及可能发生的各种并发症,提供均衡的营养物质,并能够减少麻醉术后患者的并发症、提高患者机体免疫能力、加快患者术后恢复;本发明采用的药食同源成分配伍增效后具有理气调中、促进营养吸收、降低心脏负荷、促进血液循环、提高机体抗氧化能力,增强机体免疫能力、保护神经元细胞的功效;本发明采用的新资源食品配伍增效后具有防止麻醉术后对神经系统的损伤、减轻麻醉后对学习和记忆能力的损伤、促进神经内分泌活动、调节脑和神经的生理功能、增强免疫功能、增强术后患者的抗菌和抗病毒的能力、缓解术后疼痛、促进术后恢复、增加脑部供血、预防大脑受损的功效。
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (10)
1.一种麻醉术后专用型临床营养配方,其特征在于,包括如下组分及其重量份数:40-60份蛋白质、5-15份脂肪、40-50份碳水化合物、15-25份膳食纤维、0.05-1.2份常量元素、0.01-0.05份微量元素、0.005-0.03份脂溶性维生素、0.008-0.2份水溶性维生素、0.1-1份膳食精华、0.04-0.8份药食同源成分、0.1-3份天然植物化合物以及0.06-1.32份新资源食品;
其中,所述药食同源成分包括茯苓、栀子、金银花、葛根、沙棘、鸡内金、橘皮、桑葚中的至少一种;
其中,所述新资源食品包括初乳碱性蛋白、γ-氨基丁酸、壳寡糖、杜仲雄花、竹叶黄酮、酪蛋白磷酸肽、燕麦β-葡聚糖、地龙蛋白、牡丹籽油、酵母β-葡聚糖、乳矿物盐、玛咖粉、刺梨、低聚木糖、DHA藻油、花生四烯酸油脂、诺丽果浆、磷脂酰丝氨酸、枇杷叶中的至少一种。
2.根据权利要求1所述的麻醉术后专用型临床营养配方,其特征在于,所述微量元素包括0.02-0.1份锌。
3.根据权利要求1所述的麻醉术后专用型临床营养配方,其特征在于,所述水溶性维生素包括0.003-0.01份的B族维生素。
4.根据权利要求1所述的麻醉术后专用型临床营养配方,其特征在于,所述药食同源成分包括鸡内金、沙棘、橘皮、桑葚。
5.根据权利要求4所述的麻醉术后专用型临床营养配方,其特征在于,所述药食同源成分中各组分的重量份数为:鸡内金0.01-0.2份、沙棘0.01-0.2份、橘皮0.01-0.2份、桑葚0.01-0.2份。
6.根据权利要求1所述的麻醉术后专用型临床营养配方,其特征在于,所述新资源食品包括γ-氨基丁酸、DHA藻油、花生四烯酸油脂、诺丽果浆粉、磷脂酰丝氨酸、枇杷叶粉。
7.根据权利要求6所述的麻醉术后专用型临床营养配方,其特征在于,所述新资源食品中各组分的重量份数为:γ-氨基丁酸0.01-0.15份、DHA藻油0.01-0.4份、花生四烯酸油脂0.01-0.15份、诺丽果浆粉0.01-0.4份、磷脂酰丝氨酸0.01-0.07份、枇杷叶粉0.01-0.15份。
8.根据权利要求1所述的麻醉术后专用型临床营养配方,其特征在于,还包括如下组分和重量份数的中药成分:何首乌0.05-0.1份、胡桃肉0.05-0.1份、酸枣仁0.05-0.1份、柏子仁0.05-0.1份。
9.根据权利要求1-8中任一项所述的麻醉术后专用型临床营养配方的制备方法,其特征在于,包括如下步骤:
步骤1,制备脂肪粉末;
步骤2,制备药食同源成分粉末:采用粉碎机对预定重量份数的原料进行粉碎,将粉碎的原料置于容器中,加入重量为原料重量的3~8倍的水,进行浸泡3~4小时,然后对浸泡液进行煎煮30~60min,过滤去除原料,留取煎煮液,对煎煮液进行喷雾干燥,以60~80目筛分制备药食同源成分粉末;
步骤3,制备脂溶性维生素粉末和水溶性维生素粉末:将预定重量份数的脂溶性维生素作为芯材,选用卡拉胶、阿拉伯胶作为壁材,在高压下进行2次乳化均质处理,乳化均质时间为10~15min,然后进行喷雾瞬时干燥,以60~80目筛分制备脂溶性维生素粉末;将预定重量份数的水溶性维生素作为芯材,选用麦芽糊精、脂蛋白作为壁材,混合均匀,喷雾瞬时干燥,以60~80目筛分制备水溶性维生素粉末;
步骤4,将预定重量的蛋白质和氨基酸、碳水化合物、膳食纤维、微量元素、膳食精华、天然植物化合物以及新资源食品分别制备成粒径为150~250μm的粉末;
步骤5,将步骤1~4所制得的粉末依次加入混合机混合均匀制得配方混合物,经过杀菌处理后备用;
步骤6,将所述配方混合物制备成营养粉、营养乳剂、胶囊剂、片剂、丸剂或口服液中的至少一种;
其中,步骤1~4的顺序可相互更换。
10.根据权利要求9所述的制备方法,其特征在于,所述步骤1中制备脂肪粉末具体包括如下步骤:
1)制备壁材水溶液:取麦芽糊精36g、麦芽糖浆9g、酪蛋白酸钠3g、水50mL搅拌均匀;
2)将单甘酯取0.1g(总固形物浓度为0.2%)均匀溶于6.1mL紫苏油中;
3)将吐温80取0.1g(总固形物浓度为0.2%)均匀溶于所述壁材水溶液中;
4)将添加过乳化剂单甘酯的混合植物油脂与添加过乳化剂吐温80的壁材水溶液充分混合,得到混合溶液;
5)添加稳定剂琼脂0.1g(总固形物浓度为0.2%)于所述混合溶液后,用水定容至200mL(总固形物浓度为25%),20000r/min下高速分散2分钟,得到乳状液;
6)将所述乳状液在均质压力25MPa下,均质3次,每次5分钟,得到均质乳状液;
7)将所述均质乳状液进行喷雾干燥,进风温度为195℃,出风温度为80℃,收集得到脂肪粉末。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810445029.9A CN108514109A (zh) | 2018-05-10 | 2018-05-10 | 麻醉术后专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810445029.9A CN108514109A (zh) | 2018-05-10 | 2018-05-10 | 麻醉术后专用型临床营养配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108514109A true CN108514109A (zh) | 2018-09-11 |
Family
ID=63430458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810445029.9A Pending CN108514109A (zh) | 2018-05-10 | 2018-05-10 | 麻醉术后专用型临床营养配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108514109A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109757657A (zh) * | 2019-03-15 | 2019-05-17 | 李江 | 一种孕妇临产前适用的即食米粉及其制备方法和应用 |
CN110353271A (zh) * | 2019-06-13 | 2019-10-22 | 陕西科技大学 | 一种抑制食道反流的特殊医学食品增稠组件及其制备方法 |
CN113035312A (zh) * | 2021-03-03 | 2021-06-25 | 杭州睿知科技有限公司 | 围手术期使用抗菌药物的智能管控系统 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN106983136A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种产褥期调理专用型临床营养配方及其制备方法 |
CN107440102A (zh) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | 一种更年期女性专用型临床营养配方及其制备方法 |
CN107616490A (zh) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | 一种儿童术后专用型临床营养配方及其制备方法 |
-
2018
- 2018-05-10 CN CN201810445029.9A patent/CN108514109A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN106962912A (zh) * | 2017-03-29 | 2017-07-21 | 上海奥医生物医药科技有限公司 | 一种肝病专用型临床营养配方及其制备方法 |
CN106983136A (zh) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | 一种产褥期调理专用型临床营养配方及其制备方法 |
CN107440102A (zh) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | 一种更年期女性专用型临床营养配方及其制备方法 |
CN107616490A (zh) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | 一种儿童术后专用型临床营养配方及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109757657A (zh) * | 2019-03-15 | 2019-05-17 | 李江 | 一种孕妇临产前适用的即食米粉及其制备方法和应用 |
CN109757657B (zh) * | 2019-03-15 | 2022-02-11 | 李江 | 一种孕妇临产前适用的即食米粉及其制备方法和应用 |
CN110353271A (zh) * | 2019-06-13 | 2019-10-22 | 陕西科技大学 | 一种抑制食道反流的特殊医学食品增稠组件及其制备方法 |
CN113035312A (zh) * | 2021-03-03 | 2021-06-25 | 杭州睿知科技有限公司 | 围手术期使用抗菌药物的智能管控系统 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
CN106722206A (zh) | 一种缓解消化道不适症状和/或情绪压力的组合物及其产品 | |
CN103371227A (zh) | 一种既可完善饮食结构又可调理饮食性味的纯天然饮品 | |
CN106723087A (zh) | 一种含海带膳食纤维的片剂及其制备方法 | |
CN111053190A (zh) | 用于减肥代餐的轻食组合物及其制备方法 | |
CN108514109A (zh) | 麻醉术后专用型临床营养配方及其制备方法 | |
JP2005281278A (ja) | 栄養剤、消化器剤、抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤、強筋肉剤、抗炎症剤 | |
CN106723075A (zh) | 一种双参沙棘g蛋白肉苁蓉锌硒制剂及其制备方法 | |
US20170035721A1 (en) | Composition for preventing or improving peripheral neuropathy | |
CN1742971A (zh) | 砂仁山楂冲剂及其制备工艺 | |
CN105028995A (zh) | 一种配合狗粮及其制备方法 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
KR102000170B1 (ko) | 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품 | |
CN106690121A (zh) | 一种海参沙棘虫草硒制剂及其制备工艺 | |
JP2005278604A (ja) | 健康食品 | |
CN103431393A (zh) | 一种供呼吸系统疾病患者食用的五谷杂粮全营养配方食品 | |
CN108888751B (zh) | 一种用于治疗和预防关节炎的组合物及其制备方法 | |
CN109966387A (zh) | 一种调养五脏和养心安神的配方及制备方法 | |
CN106072584A (zh) | 一种叶黄素酯和沙棘油复合型食用保健品 | |
KR101878599B1 (ko) | 메틸설포닐메테인과 만니톨의 흡수촉진 및 고미감소를 위한 공침조성물과 이의 제조방법 | |
CN109258976A (zh) | 一种鸡饲料中的中药添加剂 | |
CN103431277B (zh) | 一种供创伤、手术患者食用的五谷杂粮全营养配方食品 | |
CN103478549A (zh) | 一种供癫痫患者食用的五谷杂粮全营养配方食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180911 |
|
RJ01 | Rejection of invention patent application after publication |